eFFECTOR Therapeutics is pioneering a new class of small molecule drugs that act by selectively regulating translation, also known as protein synthesis. The company unites breakthrough insights into the mechanisms of translational control with a proven approach to product invention. We expect this fusion to yield important new therapies for cancer and other serious diseases.

(read more)


San Diego, CA – May 20, 2013
eFFECTOR Therapeutics, a newly established biopharmaceutical company, today announced the completion of a $45 million Series A financing.

(read more)